Global Morton’s Neuroma Treatment Market, By Treatment (Medication, Injection Therapy, Surgery, Others), Diagnosis (Physical Examination, Magnetic Resonance Imaging (MRI), X-Ray, Ultrasound, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.
Morton’s Neuroma Treatment Market Analysis and Size
Morton's neuroma affects the ball of the foot and is a benign yet painful ailment. It's also known as an intermetatarsal neuroma because it's found between your metatarsal bones in the ball of your foot. It's a disease that impacts one of the plantar digital nerves, which run between the long bones in the foot (metatarsals). The nerve between the third and fourth metatarsal bones is most usually affected, causing pain and numbness in the third and fourth toes. It can also cause problems in the second and third toes by affecting the nerve between the second and third metatarsal bones. It mostly affects people in their middle age, mostly women. Shoes that are overly tight or have high heels are frequently the cause of Morton's neuroma. The nerves in your feet may become crushed or irritated because of wearing these shoes. As a result of the strain on the irritated nerve, it thickens and becomes increasingly painful.
Data Bridge Market Research analyses that the global Morton’s neuroma treatment market which was USD 474.00 million in 2022, would reach up to USD 716.63 million by 2030, and is expected to undergo a CAGR of 4.70% during the forecast period. “Medication” dominates the treatment segment of the Morton’s neuroma treatment market owing to the promising therapeutic effects produced by medication. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment (Medication, Injection Therapy, Surgery, Others), Diagnosis (Physical Examination, Magnetic Resonance Imaging (MRI), X-Ray, Ultrasound, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Abbott (U.S.), Bayer AG (Germany), Johnson & Johnson Private Limited (U.S.), Boehringer Ingelheim International GmbH (Germany), AstraZeneca (U.K.),Assertio Holdings, Inc. (U.S.), Horizon Therapeutics plc (Ireland), Perrigo Company plc (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), AbbVie Inc. (U.S.), Eli Lilly and Company (U.S.) and Cipla Inc. (India)
|
|
Market Opportunities
|
|
|
|
|
Market Definition
Morton's neuroma is a painful foot condition characterized by the thickening of the tissue surrounding a nerve, commonly between the third and fourth toes. This condition is often associated with irritation or compression of the nerve, frequently caused by wearing tight or high-heeled shoes. Symptoms include sharp, burning pain in the ball of the foot, numbness, tingling, and the sensation of a lump or object inside the shoe. The pain may radiate into the toes, and symptoms may worsen during activities that put pressure on the forefoot. Diagnosis involves a physical examination and may include imaging studies. Treatment options range from conservative measures like footwear adjustments and orthotics to more invasive interventions, including corticosteroid injections or surgery in severe cases.
Global Morton’s Neuroma Treatment Market Dynamics
Drivers
- Increasing incidence and prevalence
The growing occurrence of Morton's neuroma, attributed to factors like lifestyle changes and aging, acts as a primary driver. As more individuals experience symptoms, there is a rising demand for effective treatment options. This trend emphasizes the need for accessible and advanced healthcare solutions to address the increasing prevalence of this foot condition.
- Aging population
The demographic shift toward an aging population significantly contributes to the demand for Morton's neuroma treatments. As individuals age, the risk of foot-related issues, including neuromas, rises. This demographic trend underscores the importance of developing targeted and efficient treatments to address the specific needs and challenges associated with Morton's neuroma in older adults.
Opportunities
- Advancements in medical technology
The growth of the Morton's neuroma treatment market is likely to spur advancements in medical technology, particularly in diagnostic tools and imaging techniques. Innovations such as high-resolution ultrasound or magnetic resonance imaging (MRI) may provide more accurate and detailed insights into neuroma conditions, enabling healthcare professionals to tailor treatment plans based on precise diagnostic information.
- Expanded therapeutic options
Increasing market demand offers an opportunity for the development and introduction of a diverse range of therapeutic options. This may encompass pharmacological interventions, physical therapies, and non-invasive approaches, providing a broader spectrum of choices for patients and healthcare providers. The expansion of therapeutic options aligns with the goal of tailoring treatments to individual patient needs and preferences, enhancing overall effectiveness and patient satisfaction.
Restraints/Challenges
- Limited non-invasive treatment options
The availability of non-invasive treatment options for Morton's neuroma is somewhat limited. While conservative measures such as footwear modification and orthotics are common, more advanced cases may require invasive interventions, including surgical procedures. The preference for non-invasive solutions can be a challenge for individuals seeking effective yet minimally disruptive treatments.
- Diagnostic challenges
Diagnosing Morton's neuroma can be challenging, as symptoms may overlap with other foot conditions. Achieving a precise diagnosis often requires a combination of clinical evaluation and imaging studies. The need for accurate and timely diagnosis presents a challenge in ensuring appropriate and targeted treatment plans.
This Morton’s neuroma treatment Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Morton’s neuroma treatment Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Morton’s neuroma treatment Market Scope
The Morton’s neuroma treatment Market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Injection Therapy
- Surgery
- Others
Diagnosis
- Physical Examination
- Magnetic Resonance Imaging (MRI)
- X-Ray
- Ultrasound
- Others
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Parenteral
- Others
End Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Morton’s Neuroma Treatment Market Regional Analysis/Insights
The Morton’s neuroma treatment Market is analyzed and market size insights and trends are provided by country, treatment, diagnosis, dosage, route of administration, end users and distribution channel as referenced above.
The countries covered in the Morton’s neuroma treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the Morton’s neuroma treatment market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region.
Asia-Pacific is expected to grow during the forecast period due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Morton’s neuroma treatment Market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Morton’s neuroma treatment Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Morton’s neuroma treatment Market. The data is available for historic period 2010-2020.
Competitive Landscape and Morton’s Neuroma Treatment Market Share Analysis
The Morton’s neuroma treatment Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Morton’s neuroma treatment Market.
Some of the major players operating in the Morton’s neuroma treatment Market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Abbott (U.S.)
- Bayer AG (Germany)
- Johnson & Johnson Private Limited (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- AstraZeneca (U.K.)
- Assertio Holdings, Inc. (U.S.)
- Horizon Therapeutics plc (Ireland)
- Perrigo Company plc (Ireland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Allergan (Ireland)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- AbbVie Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Cipla Inc. (India)
SKU-